RxDoctor Payments Data

Ahmed Elkeeb, MD

Retina Specialist · Columbia, MONPI 1568648699

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,750 of the $5,524 with a category attached, or 86.0%. Boehringer Ingelheim accounts for 86.0% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $4,911 and has fallen 99.2% since, to $40 in 2025.

$5,524in general payments, 2019–2025

Across 28 payments — averaging $197.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$5K
  • AbbVie$153
  • Carl Zeiss Meditec USA, Inc.$126
  • Genentech USA, Inc.$104
  • Alcon$76
  • NEW World Medical,inc.$63
  • plus $253 from 8 others
$72,094in research payments, 2019–2025

Across 34 payments — averaging $2120.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$53K
  • AbbVie$16K
  • Boehringer Ingelheim International GmbH$3K

What the payments were for

  • Consulting fees$4,75086%
  • Food & beverage$77414%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,524 in reported general payments places this provider in the 70th percentile of 45 retina specialist providers in Missouri.

See all retina specialist providers in Missouri

Medicare billing

Part B allowed, 2024
$206,420
Medicare patients
352
Services billed
2,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CombiganBrimonidine Tartrate/Timolol15$4,883
Difluprednate49$3,780
Prednisolone Acetate84$3,408
Ketorolac Tromethamine21$730
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat42$684
Prednisone23$243
Brimonidine Tartrate31$210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan$153$4,88315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 45 retina specialist providers in Missouri.

Other retina specialist in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →